Ocugen reported that its Phase 2 ArMaDa study of the sub‑retinal gene therapy OCU410 achieved a 31 % reduction in geographic atrophy lesion growth at 12 months in the optimal (medium) dose cohort, meeting the study’s primary endpoint. The trial, which enrolled 60 patients, also confirmed a clean safety profile, with no serious adverse events or drug‑related safety signals reported.
The 31 % reduction is lower than the 54 % lesion‑growth inhibition observed in the interim January analysis, a difference that has tempered investor enthusiasm. Nonetheless, the result still represents a meaningful therapeutic benefit and satisfies the regulatory criteria for progression to Phase 3, which the company plans to initiate in the third quarter of 2026.
Ocugen’s data come against a backdrop of a 2–3 million‑patient market for dry age‑related macular degeneration in the U.S. and Europe. The 31 % reduction outpaces the 15 % and 22 % lesion‑growth reductions reported for the only currently approved complement‑inhibitor therapies at 12 and 24 months, respectively, and positions OCU410 as a potentially superior option in a competitive landscape that includes other gene‑therapy candidates and approved drugs.
The company has outlined a clear regulatory roadmap: a Biologics License Application is targeted for 2028, with the Phase 3 trial slated for Q3 2026. Ocugen also continues development of OCU410ST for Stargardt disease, which has received rare pediatric disease and orphan drug designations, and it has set a broader goal of advancing three regulatory submissions within three years.
In January, Dr. Huma Qamar, Chief Medical Officer, highlighted the trial’s robust safety profile, noting that “no drug‑related serious adverse events, no inflammation signals, and no injection complications” were observed in 60 patients. Dr. Shankar Musunuri, CEO, emphasized the program’s potential, stating that the 46 % lesion‑growth reduction in the preliminary analysis “demonstrates the capability of our multi‑pathway RORA approach.” These statements underscore the company’s confidence in the therapy’s long‑term durability.
Investor reaction was muted, with market participants expressing disappointment over the lower efficacy relative to the January data. The result, while meeting the primary endpoint and confirming safety, was viewed as a step back in terms of therapeutic potency, prompting a cautious outlook for the company’s near‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.